Sight Sciences reported a total revenue of $19.6 million for Q2 2025, an 8% decrease year-over-year, primarily due to lower Surgical Glaucoma revenue impacted by Medicare coverage restrictions. Despite this, the company reduced operating expenses and saw an increase in Surgical Glaucoma ordering accounts, leading to a slightly improved net loss.

Sight Sciences reported a total revenue of $17.5 million for the first quarter of 2025, a 9% decrease year-over-year, primarily due to lower Surgical Glaucoma revenue. Despite the revenue decline, the company maintained an 86% gross margin and reduced total operating expenses by 7%.

Sight Sciences reported Q4 2024 revenue of $19.1 million, a 2% increase year-over-year. Net loss widened to $11.8 million, with an EPS loss of $0.23. Gross margin improved to 87%, primarily due to a favorable product mix shift towards higher-margin Surgical Glaucoma revenue. Operating expenses increased by 5% due to higher personnel-related costs.

Sight Sciences reported a 1% increase in revenue to $20.2 million for Q3 2024. Surgical Glaucoma revenue increased by 1%, while Dry Eye revenue decreased by 4%. The company generated positive cash flow of $0.4 million and updated its full year adjusted operating expenses guidance to $104.0 million - $106.0 million.

Sight Sciences generated $21.4 million in revenue, a 9% decrease compared to the same period last year. They achieved a gross margin of 86%, and reduced cash usage to $9.1 million. The company narrowed its full-year revenue guidance to $81.0 million to $83.0 million.

Sight Sciences reported a decrease in fourth-quarter revenue by 9% compared to the same period in the prior year, while full-year revenue increased by 14%. The company reduced operating expenses and cash used in the quarter, and secured a new credit facility. They maintained Medicare patient access to their surgical systems and saw positive clinical trial results for their technologies.

Sight Sciences generated $20.0 million in total revenue, a 7% increase compared to the same period in the prior year. The company achieved a gross margin of 86.6% and is implementing a plan to reduce operating expenses and improve cost efficiencies.

Sight Sciences reported a record second quarter revenue of $23.5 million, a 36% increase compared to the prior year period. The company achieved a gross margin of 85.6% and saw a decrease in operating expenses. They also reaffirmed their full-year revenue guidance of $89.0 million to $94.0 million.

Sight Sciences reported a 26% increase in revenue for the first quarter of 2023, driven by the adoption of surgical glaucoma and dry eye technologies. The company reaffirmed its full-year revenue guidance and expects improved operating leverage.

Sight Sciences reported strong revenue growth in Q4 2022, driven by increased adoption and utilization of its products. The company also focused on improving operating efficiency and maintaining financial discipline, resulting in reduced operating expenses. The company projects revenue for the full year 2023 to range from $89 million to $94 million, which represents growth of approximately 25% to 32% compared to 2022.

Sight Sciences reported a 43% increase in revenue compared to the third quarter of 2021, with Surgical Glaucoma revenue increasing by 37% and Dry Eye revenue increasing by 145%. The company achieved a gross margin of 84%.

Sight Sciences reported a 37% increase in revenue to $17.2 million for the second quarter of 2022, driven by growth in both Surgical Glaucoma and Dry Eye segments. Gross margin expanded to 84%. The company is focused on increasing adoption of its OMNI Surgical System and TearCare System, launching the SION surgical instrument, and advancing dry eye initiatives.

Sight Sciences reported a strong first quarter with a 72% increase in revenue compared to the prior year period, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company also expanded its gross margin to 80%.

Sight Sciences reported a strong fourth quarter and full year 2021, with significant revenue growth and gross margin expansion. The company achieved FDA clearances for OMNI and TearCare, made progress in clinical trials, and advanced R&D efforts.

Sight Sciences reported a strong third quarter with record revenue of $13.1 million, a 51% increase compared to the prior year. The company saw significant growth in surgical glaucoma revenue and expanded its gross margin to 84%. However, operating expenses also increased, resulting in a net loss of $17.2 million.

Sight Sciences reported a significant increase in revenue for the second quarter of 2021, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company's gross margin also saw substantial improvement. They completed an IPO raising $253 million.